Adoption of spironolactone therapy for older patients with heart failure and left ventricular systolic dysfunction in the United States, 1998-2001

Circulation

Volumn 112, Issue 1, 2005, Pages 39-47

  Masoudi, Frederick A ^a,b,c,d   Gross, Cary P ^e,f   Wang, Yongfei ^e   Rathore, Saif S ^e   Havranek, Edward P ^a,b,c   Foody, JoAnne Micale ^e,g   Krumholz, Harlan M ^c,e,f  

^a DENVER HEALTH MEDICAL CENTER   (United States)

^b UNIVERSITY OF COLORADO   (United States)

^c Colorado Health Outcomes Program ^*  (United States)

^d Division of General Internal Medicine   (United States)

^e YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f YALE NEW HAVEN HOSPITAL   (United States)

^g VA CONNECTICUT HEALTHCARE SYSTEM   (United States)

Author keywords

Aging; Aldosterone antagonists; Heart failure; Potassium

Indexed keywords

ALDOSTERONE ANTAGONIST; CREATININE; POTASSIUM; SPIRONOLACTONE;

AGED; ARTICLE; CLINICAL TRIAL; COMORBIDITY; EVALUATION; FEMALE; GLOMERULUS FILTRATION RATE; HEART FAILURE; HEART LEFT VENTRICLE OVERLOAD; HOSPITAL DISCHARGE; HUMAN; HYPERKALEMIA; KIDNEY DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; MEDICARE; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; NURSING; PRESCRIPTION; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; SAMPLING; SYSTOLIC BLOOD PRESSURE;

AGED; AGED, 80 AND OVER; ALDOSTERONE ANTAGONISTS; COHORT STUDIES; CREATININE; DIURETICS; FEMALE; FOLLOW-UP STUDIES; HEART FAILURE, CONGESTIVE; HUMANS; MALE; PATIENT SELECTION; POTASSIUM; PRESCRIPTIONS, DRUG; RANDOMIZED CONTROLLED TRIALS; RISK ASSESSMENT; SPIRONOLACTONE; UNITED STATES; VENTRICULAR DYSFUNCTION, LEFT;

EID: 21844459736     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.104.527549     Document Type: Article

References (29)

1. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J. Wittes J. The effect of spironolactone on morbidity and mortality in patients with severe heart failure: Randomized Aldactone Evaluation Study Investigators. N Engl J Med. 1999;341:709-717.
2. Geraci JM, Knowlton AA. Spironolactone for heart failure: spiraling out of control. Chest. 2000;118:1522-1523.
3. Berry C, McMurray J. Serious adverse events experienced by patients with chronic heart failure taking spironolactone. Heart. 2001;85:e8-e9.
4. Bozkurt B, Agoston I, Knowlton AA. Complications of inappropriate use of spironolactone in heart failure: when an old medicine spirals out of new guidelines. J Am Coll Cardiol 2003;41:211-214.
5. Svensson M, Gustafsson F, Galatius S, Hildebrandt PR, Atar D. Hyperkalaemia and impaired renal function in patients taking spironolactone for congestive heart failure: retrospective study. BMJ. 2003;327: 1141-1142.
6. Wrenger E, Muller R, Moesenthin M, Welte T, Frolich JC, Neumann KH. Interaction of spironolactone with ACE inhibitors or angiotensin receptor blockers: analysis of 44 cases. BMJ. 2003;327:147-149.
7. Blaustein DA, Babu K, Reddy A, Schwenk MH, Avram MM. Estimation of glomerular filtration rate to prevent life-threatening hyperkalemia due to combined therapy with spironolactone and angiotensin-converting enzyme inhibition or angiotensin receptor blockade. Am J Cardiol. 2002; 90:662-663.
8. Obialo CI, Ofili EO, Mirza T. Hyperkalemia in congestive heart failure patients aged 63 to 85 years with subclinical renal disease. Am J Cardiol. 2002;90:663-665.
9. Vanpee D, Swine CH. Elderly heart failure patients with drug-induced serious hyperkalemia. Aging Clin Exp Res. 2000;12:315-319.
10. Juurlink DN, Mamdani MM, Lee DS, Kopp A, Austin PC, Laupacis A, Redelmeier DA. Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. N Engl J Med. 2004;351:543-551.
11. Hunt SA, Baker DW, Chin MH, Cinquegrani MP, Feldman AM, Francis GS, Ganiats TG, Goldstein S, Gregoratos G, Jessup ML, Noble RJ, Packer M, Silver MA, Stevenson LW, Gibbons RJ, Antman EM, Alpert JS, Faxon DP, Fuster V, Jacobs AK, Hiratzka LF, Russell RO, Smith SC Jr. ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult: executive summary a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1995 Guidelines for the Evaluation and Management of Heart Failure). Circulation. 2001;104: 2996-3007.
12. Masoudi FA, Havranek EP, Wolfe P, Gross CP, Rathore SS, Steiner JF, Ordin DL, Krumholz HM. Most hospitalized older persons do not meet the enrollment criteria for clinical trials in heart failure. Am Heart J. 2003;146:250-257.
13. Havranek EP, Masoudi FA, Westfall KA, Wolfe P, Ordin DL, Krumholz HM. Spectrum of heart failure in older patients: results from the National Heart Failure project. Am Heart J. 2002;143:412-417.
14. Rathore SS, Foody JM, Wang Y, Smith GL, Herrin J, Masoudi FA, Wolfe P, Havranek EP, Ordin DL, Krumholz HM. Race, quality of care, and outcomes of elderly patients hospitalized with heart failure. JAMA. 2003; 289:2517-2524.
15. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 2002;39(suppl 1):S1-S266.
16. Kenward K. The scope of the data available in the AMA's Physician Masterfile. Am J Public Health. 1996;86:1481-1482.
17. Baldwin LM, Adamache W, Klabunde CN, Kenward K, Dahlman C, Warren L. Linking physician characteristics and Medicare claims data: issues in data availability, quality, and measurement. Med Care. 2002; 40(suppl):IV-82-IV-95.
18. Iezzoni LI. Risk Adjustment for Measuring Health Care Outcomes, 2nd ed. Chicago: Health Administration Press; 1997.
19. American Hospital Association. The AHA Annual Survey Database: Fiscal Year 1998 Documentation. Chicago: Health Forum, AHA; 1999.
20. American Hospital Association. The AHA Annual Survey Database: Fiscal Year 2000 Documentation. Chicago: Health Forum, AHA; 2001.
21. Tan SY, Burton M. Hyporeninemic hypoaldosteronism: an overlooked cause of hyperkalemia. Arch Intern Med. 1981;141:30-33.
22. Nichols GA, Hillier TA, Erbey JR, Brown JB. Congestive heart failure in type 2 diabetes: prevalence, incidence, and risk factors. Diabetes Care. 2001;24:1614-1619.
23. Dries DL, Exner DV, Domanski MJ, Greenberg B, Stevenson LW. The prognostic implications of renal insufficiency in asymptomatic and symptomatic patients with left ventricular systolic dysfunction. J Am Coll Cardiol. 2000;35:681-689.
24. Hillege HL, Girbes AR, de Kam PJ, Boomsma F, de Zeeuw D, Charlesworth A, Hampton JR, van Veldhuisen DJ. Renal function, neurohormonal activation, and survival in patients with chronic heart failure. Circulation. 2000;102:203-210.
25. Schepkens H, Vanholder R, Billiouw JM, Lameire N. Life-threatening hyperkalemia during combined therapy with angiotensin-converting enzyme inhibitors and spironolactone: an analysis of 25 cases. Am J Med. 2001;110:438-441.
26. Jencks SF, Huff ED, Cuerdon T. Change in the quality of care delivered to Medicare beneficiaries, 1998-1999 to 2000-2001. JAMA. 2003;289: 305-312.
27. Wenger NS, Shekelle PG. Assessing care of vulnerable elders: ACOVE project overview. Ann Intern Med. 2001;135(pt 2):642-646.
28. Shekelle PG, MacLean CH, Morton SC, Wenger NS. ACOVE quality indicators. Ann Intern Med. 2001;135(pt 2):653-667.
29. Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, Bittman R, Hurley S, Kleiman J, Gatlin M. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 2003;348:1309-1321.